IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i19p12803-d934885.html
   My bibliography  Save this article

Inhaled Nitric Oxide for Clinical Management of COVID-19: A Systematic Review and Meta-Analysis

Author

Listed:
  • Jaber S. Alqahtani

    (Department of Respiratory Care, Prince Sultan Military College of Health Sciences, Dammam 34313, Saudi Arabia)

  • Abdulelah M. Aldhahir

    (Respiratory Therapy Department, Faculty of Applied Medical Sciences, Jazan University, Jazan 45142, Saudi Arabia)

  • Shouq S. Al Ghamdi

    (Anesthesia Technology Department, Prince Sultan Military College of Health Sciences, Dammam 34313, Saudi Arabia)

  • Salma AlBahrani

    (Department of Internal Medicine, King Fahad Military Medical Complex, Dhahran 31932, Saudi Arabia)

  • Ibrahim A. AlDraiwiesh

    (Department of Respiratory Care, Prince Sultan Military College of Health Sciences, Dammam 34313, Saudi Arabia)

  • Abdullah A. Alqarni

    (Department of Respiratory Therapy, Faculty of Medical Rehabilitation Sciences, King Abdulaziz University, Jeddah 22254, Saudi Arabia)

  • Kamaluddin Latief

    (Global Health and Health Security Department, College of Public Health, Taipei Medical University, Taipei 11031, Taiwan
    Centre for Family Welfare, Faculty of Public Health, University of Indonesia, Depok 16424, Indonesia)

  • Reynie Purnama Raya

    (Institute for Global Health, Faculty of Population Health Sciences, University College London, London NW3 2PF, UK
    Faculty of Science, Universitas ‘Aisyiyah Bandung, Bandung 40264, Indonesia)

  • Tope Oyelade

    (Institute for Liver and Digestive Health, Division of Medicine, University College London, London NW3 2PF, UK)

Abstract

Background: Severe COVID-19 is associated with hypoxemia and acute respiratory distress syndrome (ARDS), which may predispose multiorgan failure and death. Inhaled nitric oxide (iNO) is a clinical vasodilator used in the management of acute respiratory distress syndrome (ARDS). This study evaluated the response rate to iNO in patients with COVID-19-ARDS. Method: We searched Medline and Embase databases in May 2022, and data on the use of iNO in the treatment of ARDS in COVID-19 patients were synthesized from studies that satisfied predefined inclusion criteria. A systematic synthesis of data was performed followed by meta-analysis. We performed the funnel plot and leave-one-out sensitivity test on the included studies to assess publication bias and possible exaggerated effect size. We compared the effect size of the studies from the Unites States with those from other countries and performed meta-regression to assess the effect of age, year of publication, and concomitant vasodilator use on the effect size. Results: A total of 17 studies (including 712 COVID-19 patients) were included in this systematic review of which 8 studies (involving 265 COVID-19 patients) were subjected to meta-analysis. The overall response rate was 66% (95% CI, 47–84%) with significantly high between-studies heterogeneity (I2 = 94%, p < 0.001). The funnel plot showed publication bias, although the sensitivity test using leave-one-out analysis showed that removing any of the study does not remove the significance of the result. The response rate was higher in the Unites States, and meta-regression showed that age, year of publication, and use of concomitant vasodilators did not influence the response rate to iNO. Conclusion: iNO therapy is valuable in the treatment of hypoxemia in COVID-19 patients and may improve systemic oxygenation in patients with COVID-19-ARDS. Future studies should investigate the mechanism of the activity of iNO in COVID-19 patients to provide insight into the unexplored potential of iNO in general ARDS.

Suggested Citation

  • Jaber S. Alqahtani & Abdulelah M. Aldhahir & Shouq S. Al Ghamdi & Salma AlBahrani & Ibrahim A. AlDraiwiesh & Abdullah A. Alqarni & Kamaluddin Latief & Reynie Purnama Raya & Tope Oyelade, 2022. "Inhaled Nitric Oxide for Clinical Management of COVID-19: A Systematic Review and Meta-Analysis," IJERPH, MDPI, vol. 19(19), pages 1-16, October.
    • Handle: RePEc:gam:jijerp:v:19:y:2022:i:19:p:12803-:d:934885
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/19/12803/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/19/19/12803/
    Download Restriction: no
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:19:p:12803-:d:934885. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.